MARSHALL WACE, LLP - RIGEL PHARMACEUTICALS INC ownership

RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 96 filers reported holding RIGEL PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of RIGEL PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$38,898
-82.9%
36,017
-79.1%
0.00%
Q1 2023$228,005
-9.2%
172,731
+149.5%
0.00%
-100.0%
Q3 2021$251,000
+402.0%
69,222
+153.5%
0.00%
Q2 2020$50,000
-96.2%
27,304
-96.1%
0.00%
-100.0%
Q3 2019$1,326,000
-59.3%
709,026
-43.1%
0.01%
-63.0%
Q2 2019$3,254,000
-44.8%
1,246,563
-45.6%
0.03%
-3.6%
Q1 2019$5,892,000
+662.2%
2,292,794
+582.0%
0.03%
+250.0%
Q4 2018$773,000
-9.7%
336,169
+26.0%
0.01%
+100.0%
Q3 2018$856,000
+1158.8%
266,792
+1016.0%
0.00%
+300.0%
Q2 2018$68,000
-79.1%
23,906
-82.6%
0.00%
-50.0%
Q4 2016$326,000
-57.4%
137,046
-34.3%
0.00%
-60.0%
Q3 2016$765,000
-56.6%
208,510
-75.4%
0.01%
-70.6%
Q1 2016$1,764,000
-19.8%
847,926
+16.8%
0.02%
-19.0%
Q4 2015$2,200,000
+22.6%
726,1280.0%0.02%
-4.5%
Q3 2015$1,794,000
-19.9%
726,128
+4.1%
0.02%
-24.1%
Q2 2015$2,239,000
+9.5%
697,392
+21.7%
0.03%
+7.4%
Q1 2015$2,045,000
+147.9%
572,947
+57.6%
0.03%
+145.5%
Q4 2014$825,000
+26.3%
363,519
+102.2%
0.01%
+10.0%
Q2 2014$653,000179,7640.01%
Other shareholders
RIGEL PHARMACEUTICALS INC shareholders Q4 2014
NameSharesValueWeighting ↓
CM Management, LLC 1,500,000$1,620,0001.72%
Soleus Capital Management, L.P. 14,803,015$15,987,2561.48%
ARMISTICE CAPITAL, LLC 17,136,000$18,506,8800.28%
SPHERA FUNDS MANAGEMENT LTD. 1,228,126$1,326,3760.24%
GSA CAPITAL PARTNERS LLP 971,441$1,0490.09%
NJ State Employees Deferred Compensation Plan 200,000$216,0000.03%
Providence Wealth Advisors, LLC 27,500$29,0130.03%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 1,151,765$1,243,9060.03%
XTX Topco Ltd 164,238$177,3770.03%
JACOBS LEVY EQUITY MANAGEMENT, INC 3,369,076$3,638,6020.02%
View complete list of RIGEL PHARMACEUTICALS INC shareholders